Eli Lilly & Co.’s Valuation after Its 4Q16 Earnings Release PART 9 OF 10
Eli Lilly & Co.’s Recent Developments
As we discussed earlier in this series, Eli Lilly & Co.’s (LLY) segment-wise performance was positive for its Human Pharmaceuticals and Animal Health segments. The chart below details some of the company’s recent developments.
Recent commercial developments for Eli Lilly & Co. (LLY) include the following:
- Eli Lilly and Boehringer Ingelheim launched Jardiance in the US markets for a new indication of reducing the risk of cardiovascular death in patients with type 2 diabetes.
- Eli Lilly and Boehringer Ingelheim also launched Basaglar in the US market.
- LLY launched Taltz in Japan for psoriasis and psoriatic arthritis.
- Eli Lilly launched Latruvo in the US and European markets for the treatment of soft tissue sarcoma.
- Eli Lilly and Aratana (PETX) announced the availability of Galliprant, a drug used by veterinarians in the US markets to manage pain and inflammation in canine osteoarthritis.
Following are the recent regulatory developments for Eli Lilly:
- The FDA approved Synjardy XR for improving glycemic control in patients with type 2 diabetes. Synjardy is developed in collaboration with Boehringer Ingelheim.
- The European Commission approved Glyxambi, a combination drug of Jardiance and Tradjenta developed in collaboration with Boehringer Ingelheim, for improving blood sugar control in patients with type 2 diabetes.
- The FDA extended the review period of the new drug application for Baricitinib for the treatment of patients with moderate to severe rheumatoid arthritis. The action date is expected to occur in 2Q17.
Eli Lilly & Co. (LLY) announced that EXPEDITION3, a phase III clinical trial evaluating Solanezumab for the treatment of mild dementia in patients with Alzheimer’s disease, did not meet its primary endpoint.
For diversified exposure to LLY, investors can consider the PowerShares Dynamic Pharmaceuticals ETF (PJP) which holds ~5.8% of its total assets in Eli Lilly, ~5.1% in Pfizer (PFE), ~5.1% in Merck & Co. (MRK), and ~4.9% in Gilead Sciences (GILD).
In the final part of this series, we’ll look at Eli Lilly & Co.’s (LLY) valuations following its 4Q16 earnings report.